Medical University of Vienna
Vienna, 1090, Austria
NCT Number: NCT00375323
The purpose of the study is to compare the effects of recombinant factor VIIa (NovoSeven) on restoring coagulation activation between patients with hemophilia A and antibodies to factor VIII and normal subjects (controls) by use of an in vivo method.
Looking for future studies?
Notify Me18 year and older
Male
Interventional
Phase 3
Vienna, 1090, Austria
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Medical University of Vienna
Other
Effects of Recombinant Factor VIIa (NovoSeven) on Restoring Coagulation Activation in Patients With Hemophilia A and Antibodies to Factor VIII
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05147662
Blood Coagulation Disorders, Blood Coagulation Disorders, Inherited
Orlando, Florida, United States
View Trial DetailsNCT06579144
Blood Coagulation Disorders, Blood Coagulation Disorders, Inherited
Sofia, Bulgaria
View Trial DetailsNCT03315455
Blood Coagulation Disorders, Blood Coagulation Disorders, Inherited
Beijing, China
View Trial DetailsNCT04158648
Blood Coagulation Disorders, Blood Coagulation Disorders, Inherited
Los Angeles, California, United States
View Trial Details